{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 73 of 129', 'significance of ECG abnormalities. If a result is abnormal at the screening visit and', \"considered by the investigator to be clinically significant, it will be up to the investigator's\", 'discretion if the subject should be enrolled into the trial (respecting exclusion criterion', 'no. 26); if such a subject is enrolled, the investigator will provide a justification in the medical', 'record.', 'Clinically significant abnormal ECG findings at the first screening visit will be documented', 'as medical history in the eCRF. If an abnormal ECG finding at any other visit than the first', 'screening visit is considered by the investigator to be clinically significant, it will be reported', 'as an AE in accordance with Section 11.2. Further, any clinically significant deterioration of a', 'pre-existing condition as well as any new clinically significant sign, symptom, or illness', 'observed after screening will be reported as an AE in accordance with Section 11.2.', 'Test dummy transmissions will be undertaken prior to trial conduct to ensure that', 'transmissions can be made and that date and time settings are correctly set.', 'The collection and transmission of ECG data will be described in a separate ECG manual.', '10.4.4 Pregnancy test', 'A serum pregnancy test must be taken at the screening visit in female subjects of', 'child-bearing potential as described in the schedule of procedures in Section 4.', 'A urine pregnancy test (human chorionic gonadotropin; dipstick) must be performed at the', 'trial site at baseline prior to randomisation in female subjects of child-bearing potential. The', 'test must be repeated every 4 weeks as shown in the schedule of procedures in Section 4.', 'Note that pregnant subjects must discontinue the IMP and NIMP immediately (Section 9.7.1).', '10.4.5 Laboratory testing', 'The following safety samples will be analysed by a central laboratory: chemistry,', 'haematology, serology, and serum pregnancy, see Panel 9 for an overview of the individual', 'laboratory parameters assessed in this trial. Urine samples will be tested at the trial site with a', 'dipstick; if abnormal, a urine sample will be sent to the central laboratory for further analysis.', 'A laboratory manual will be provided to the sites that specifies the procedures for collection,', 'processing, storage, and shipment of samples, as well as laboratory contact information', 'specific to this trial.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 74 of 129', 'Samples for laboratory testing will be collected according to the schedule of procedures', '(Section 4).', \"The investigator must evaluate all results outside the reference range ('clinically significant'\", 'or \"not clinically significant\\') and sign and date. The signed and dated version will be filed', \"with the investigator's trial documentation. Clinically significant abnormal tests must be\", 'repeated to confirm the abnormality.', 'Panel 9 Central laboratory testing', 'Chemistry', 'Haematology', 'Sodium', 'Erythrocytes', 'Potassium', 'Haematocrit', 'Creatinine', 'Haemoglobin', 'Urea nitrogen', 'Erythrocyte mean corpuscular volume', 'Calcium', 'Erythrocyte mean corpuscular haemoglobin concentration', 'Alkaline phosphatase', 'Leukocytes', 'Aspartate aminotransferase', 'Neutrophils, neutrophils/total cells', 'Alanine aminotransferase', 'Lymphocytes, lymphocytes/total cells', 'Gamma glutamyl transferase', 'Monocytes, monocytes/total cells', 'Bilirubin1', 'Eosinophils, eosinophils/total cells', 'Lactate dehydrogenase', 'Basophils, basophils/total cells', 'Cholesterol', 'Thrombocytes', 'LDL cholesterol', 'Serology', 'HDL cholesterol', 'Hepatitis B virus surface antigen4', 'Triglycerides', 'Hepatitis B virus surface antibody4', 'Glucose (non-fasting)', 'Hepatitis B virus core antibody4', 'Albumin', 'Hepatitis C virus antibody4', 'Protein', 'HIV-1 antibody4', 'Tryptase\u00b2', 'HIV-2 antibody4', 'Immunoglobulin E5', 'Urinalysis\u00b3', 'Serum pregnancy test (females only)', 'Protein', 'Choriogonadotropin beta', 'Glucose', 'Ketones', 'Occult blood', 'Leukocytes', 'Nitrite', '1) If bilirubin is above upper limit of normal, direct and indirect bilirubin will also be measured.', '2)', 'Only measured in case of suspected anaphylaxis (Section 9.1.3.1).', '3) Urine samples will be tested at the trial site (dipstick). In case of abnormal dipstick results, a urine sample', 'will be sent to the central laboratory for microscopic examination (leukocytes, erythrocytes, and casts).', '4) Measured at screening only.', '5) Not measured at screening.', 'Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}